A Case of Transient Myeloproliferative Disorder Associated with Clonal Trisomy 21 in a Chromosomally Normal Newborn.
10.15264/cpho.2018.25.2.191
- Author:
Jihyun PARK
1
;
Yoo Rha HONG
;
Seom Gim KONG
Author Information
1. Department of Pediatrics, Kosin University College of Medicine, Busan, Korea. ana313@hanmail.net
- Publication Type:Case Report
- Keywords:
Myeloproliferative disorder;
Infant;
Newborn;
Chromosome 21;
GATA1 transcription factor
- MeSH:
Chromosomes, Human, Pair 21;
Down Syndrome*;
Drug Therapy;
GATA1 Transcription Factor;
Hepatomegaly;
Humans;
Infant;
Infant, Newborn*;
Leukemia;
Leukocytosis;
Mosaicism;
Myeloproliferative Disorders*;
Trisomy*
- From:Clinical Pediatric Hematology-Oncology
2018;25(2):191-196
- CountryRepublic of Korea
- Language:English
-
Abstract:
Transient myeloproliferative disorder (TMD) is similar to congenital leukemia, with leukocytosis, increased peripheral blast cells, and hepatomegaly in the neonatal period. Although TMD occurs only in patients with Down syndrome and trisomy 21 mosaicism, there have been reports of congenital leukemia with trisomy 21 limited to hematopoietic cells showing spontaneous resolution. We identified trisomy 21 in the leukemic cells in a patient with congenital leukemia. As there was no other gene abnormality, we stopped chemotherapy, and the disease resolved spontaneously. We reviewed the cases of clonal trisomy 21 TMD and found that their clinical features were similar to those of TDM associated with Down syndrome. In conclusion, in a phenotypically normal patient with suspected congenital leukemia, it is necessary to confirm the presence of 21 trisomy. If the neonate has only trisomy 21 without other gene abnormalities, intensive chemotherapy may not be required.
